RG-239

Overview

RG-239 is an orally active TGR5 agonist with an EC 50 of 120 nM, significantly outperforming Betulinic acid ( HY-10529 ) ( EC 50 = 1.04 μM). RG-239 demonstrates higher selectivity for TGR5 compared to the FXRα. RG-239 increases mitochondrial activity in adipocytes and promotes neurite outgrowth at higher concentrations. RG-239 inhibits LPS ( HY-D1056 )-induced iNOS expression and nitrite production in Raw264.7 and microglia cells. RG-239 can be used for the study of type 2 diabetes [1][2][3][4][5] .

Application

Products | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Signaling Pathways > GPCR/G Protein | Products > Research Areas > Metabolic Disease | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > G protein-coupled Bile Acid Receptor 1

Product Information

• Catalog No.: HY-177050
• CAS No.: 1199222-56-4
• Molecular Formula: C33H52O3
• Molecular Weight: 496.76
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source